Improving Cancer Patient Care: Trade-Offs Between Efficacy and Toxicity

Friday, February 12, 2016: 1:00 PM-2:30 PM
Wilson B (Marriott Wardman Park)
Remarkable advances in molecular biology are greatly improving cancer care. However, a significant challenge remains: the long-term toxicity risks of treatments. There is an urgent need to identify these long-term risks and to understand toxicologic mechanisms following exposure to cancer therapies, both for clinically-approved and emerging agents. Toward this end, a leading team of U.S. and European researchers has addressed the crucial goal of comprehensively describing toxicity patterns following treatment with two main classes of angiogenesis inhibitors. In this symposium, researchers present these advances, discussing the development of a new panel of toxicological markers for angiogenesis inhibitors that have been clinically approved as cancer treatments.
Gabriela Chira, European Commission
Bonnie Ky, Hospital of the University of Pennsylvania
The Role of Biomarkers to Detect Cardiotoxicity with Cancer Therapy